AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1)

Revance Therapeutics Inc. must pay AbbVie Inc.'s Allergan unit $56 million after a federal jury in Delaware rejected arguments for voiding three patents Revance’s Botox rival infringes.

The verdict, issued July 18 in the US District Court for the District of Delaware, followed a weeklong trial over the validity of US Patent Nos. 7,354,740, 11,203,748, and 11,147,878, which cover methods and formulations for botulinum toxin products like Botox. Jurors upheld all three patents and found Allergan Inc. had proved it was entitled to $56 million in royalties from sales of Revance’s Daxxify through the end of ...